in our free newsletter.

Thousands benefit from our email every week.

  • Discounts and special offers
  • Subscriber-only articles and interviews
  • Breaking news and trending topics

Already a subscriber?

By signing up, you accept Moneywise's Terms of Use, Subscription Agreement, and Privacy Policy.

Not interested ?

The government has been covering the costs

The American government has covered the cost of vaccines distributed in the country since they were developed and started being distributed in late 2020. It bought more than 500 million doses from Pfizer, and paid between $20 and $30 each.

According to the Centers for Disease Control and Prevention, more than 265 million people, or 80% of the U.S. population, are fully vaccinated against COVID-19. But fewer than 20 million have taken the latest booster, signaling that demand is dropping precipitously.

And while the cost seems astronomical, Pfizer reportedly said that it expects people who have private health insurance or coverage through public programs like Medicare or Medicaid won’t have to pay out of pocket for their shots.

More: 3 healthcare stocks that could boost your portfolio

Meet Your Retirement Goals Effortlessly

The road to retirement may seem long, but with WiserAdvisor, you can find a trusted partner to guide you every step of the way

WiserAdvisor matches you with vetted financial advisors that offer personalized advice to help you to make the right choices, invest wisely, and secure the retirement you've always dreamed of. Start planning early, and get your retirement mapped out today.

Get Started

Fewer people getting boosted

Vaccine producers have been in a bit of a pickle. As demand for the vaccine has waned, investors' concerns about a drop in earnings have been growing.

Analysts surveyed by Factset had said they expected the company’s sales to decline given the anticipated slowdown in vaccinations. And while the price hike will help the company cushion the blow of softening demand, the announced increase by Pfizer was higher than many people expected.

And it will likely have repercussions for other vaccine manufacturers, like Moderna.

Moderna’s shares are down 46% this year — but the company did see a 9% boost last week when news of Pfizer’s plans was released. Moderna, for its part, is also expected to raise the price of its vaccine to a more affordable $60, according to Barron’s.

And while this might be comforting news for investors, it’s not all that comforting for anyone who still needs a shot or a boost.

Sponsored

Follow These Steps if you Want to Retire Early

Secure your financial future with a tailored plan to maximize investments, navigate taxes, and retire comfortably.

Zoe Financial is an online platform that can match you with a network of vetted fiduciary advisors who are evaluated based on their credentials, education, experience, and pricing. The best part? - there is no fee to find an advisor.

About the Author

Lauren Bird

Lauren Bird

Staff Reporter

Lauren Bird was a former reporter for Moneywise.com. Before writing about personal finance Lauren reported and produced for CBC and BBC Radio. Her work has also appeared in The Atlantic.

What to Read Next

Disclaimer

The content provided on Moneywise is information to help users become financially literate. It is neither tax nor legal advice, is not intended to be relied upon as a forecast, research or investment advice, and is not a recommendation, offer or solicitation to buy or sell any securities or to adopt any investment strategy. Tax, investment and all other decisions should be made, as appropriate, only with guidance from a qualified professional. We make no representation or warranty of any kind, either express or implied, with respect to the data provided, the timeliness thereof, the results to be obtained by the use thereof or any other matter.